Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

AstraZeneca to Pay Daiichi-Sankyo $6.9 billion for Shared Rights to a New Cancer Drug

AstraZeneca Strikes $6.9 Billion Cancer Deal With Japanese Drugmaker. Deal for part of the rights to Daiichi Sankyo’s antibody drug is part of Astra’s heavy investment in cancer research. In a move...

Nobel Laureate is Demanding More Money from Ono Pharma for Cancer Drug

Nobel laureate Tasuku Honjo said Wednesday he is involved in a dispute over license fees under a patent agreement with Ono Pharmaceutical Co., which sells a cancer treatment drug developed based on hi...

AZ and MSD’s Drug Delays Pancreatic Cancer Progression

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial ...

Peloton Secures $150m for Unique Drug Development

Peloton Therapeutics, Inc., a drug discovery and development company advancing first-in-class oral medicines for cancer and other serious conditions, announced the closing of an oversubscribed $150 mi...

Keytruda Received Another FDA Approval

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment ...

Priority Review for Personilized Med of Genentech

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib f...

Launch of Company Focusing on Preventing Cancer Metastasis

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched on February 8 with $60.75M in Series A funding led by ARCH Venture Partners. Hi...

Russian Scientists Developed Cancer Drug

Russian scientists have developed a new drug for the treatment of cancer, which is comparable to the drug whose creators were awarded the Nobel Prize last year, and its certification is expected to ta...

EC Approved Clovis Drug for Relapsed Ovarian Cancer

Clovis Oncology has secured approval from the European Commission (EC) for its Rubraca (rucaparib) as maintenance treatment for women with relapsed ovarian cancer. The second indication of Rubraca ...

Expanded Indication from EC for Amgen’s Drug

Amgen announced that the European Commission (EC) has approved an expanded indication for BLINCYTO (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19...

Redx to Restart Cancer Drug Trial

Redx has secured approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to restart a phase 1/2a trial for its cancer candidate RXC004 in advanced solid tumors. An oral po...

US Tries First Digital Oncology Drugs

Cancer patients in the US are trialling digital oncology drugs for the first time, collecting data on patients in a bid to improve outcomes and help adherence. The new technology from Proteus Digit...

Samsung Cancer Drug Approved by FDA

The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers. Ontruzant, which will be marketed in the US by Me...

Lilly’s Cancer Drug Failed Trial

Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting th...

Acrotech to Acquire 7 FDA-Approved Spectrum’s Drugs

Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m. Under the deal...

Keytruda to Reduce Death Risk by 31%

Merck
Merck, known as MSD outside the United States and Canada, announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherap...